WEST PHARMACEUTICAL SERVICES, INC. Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), after Adjustments and Tax
WEST PHARMACEUTICAL SERVICES, INC. (WST) reported Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), after Adjustments and Tax of $1.00 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-17.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax · last filed 2026-02-17
- WEST PHARMACEUTICAL SERVICES, INC. other comprehensive income (loss), derivative, excluded component, increase (decrease), after adjustments and tax for the quarter ending 2025-03-31 was $2.50M.
- WEST PHARMACEUTICAL SERVICES, INC. other comprehensive income (loss), derivative, excluded component, increase (decrease), after adjustments and tax for the quarter ending 2024-12-31 was -$4.50M, a 381.25% decline year-over-year.
- WEST PHARMACEUTICAL SERVICES, INC. other comprehensive income (loss), derivative, excluded component, increase (decrease), after adjustments and tax for the quarter ending 2024-09-30 was $6.50M, a 441.67% increase year-over-year.
- WEST PHARMACEUTICAL SERVICES, INC. other comprehensive income (loss), derivative, excluded component, increase (decrease), after adjustments and tax for the quarter ending 2024-06-30 was -$2.60M.
- WEST PHARMACEUTICAL SERVICES, INC. other comprehensive income (loss), derivative, excluded component, increase (decrease), after adjustments and tax for fiscal 2025 was $1.00M.
- WEST PHARMACEUTICAL SERVICES, INC. other comprehensive income (loss), derivative, excluded component, increase (decrease), after adjustments and tax for fiscal 2024 was -$2.50M.
- WEST PHARMACEUTICAL SERVICES, INC. other comprehensive income (loss), derivative, excluded component, increase (decrease), after adjustments and tax for fiscal 2023 was -$200.00K, a 114.29% decline from fiscal 2022.
- WEST PHARMACEUTICAL SERVICES, INC. other comprehensive income (loss), derivative, excluded component, increase (decrease), after adjustments and tax for fiscal 2022 was $1.40M, a 100.00% increase from fiscal 2021.
| Period end | Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), after Adjustments and Tax 3 month | Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), after Adjustments and Tax 6 month | Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), after Adjustments and Tax 9 month | Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), after Adjustments and Tax 12 month |
|---|---|---|---|---|
| 2025-12-31 | $1.00M 10-K · filed 2026-02-17 | |||
| 2025-03-31 | $2.50M 10-Q · filed 2025-04-24 | -$2.00M derived: sum of 2 quarters · filed 2026-02-17 | $4.50M derived: sum of 3 quarters · filed 2026-02-17 | $1.90M derived: sum of 4 quarters · filed 2026-02-17 |
| 2024-12-31 | -$4.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | $2.00M derived: sum of 2 quarters · filed 2026-02-17 | -$600.00K derived: sum of 3 quarters · filed 2026-02-17 | -$2.50M 10-K · filed 2026-02-17 |
| 2024-09-30 | $6.50M 10-Q · filed 2024-10-24 | $3.90M derived: sum of 2 quarters · filed 2024-10-24 | $2.00M 10-Q · filed 2024-10-24 | $3.60M derived: sum of 4 quarters · filed 2026-02-17 |
| 2024-06-30 | -$2.60M 10-Q · filed 2024-07-25 | -$4.50M 10-Q · filed 2024-07-25 | -$2.90M derived: sum of 3 quarters · filed 2026-02-17 | -$1.70M derived: sum of 4 quarters · filed 2026-02-17 |
| 2024-03-31 | -$1.90M 10-Q · filed 2025-04-24 | -$300.00K derived: sum of 2 quarters · filed 2026-02-17 | $900.00K derived: sum of 3 quarters · filed 2026-02-17 | -$1.90M derived: sum of 4 quarters · filed 2026-02-17 |
| 2023-12-31 | $1.60M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | $2.80M derived: sum of 2 quarters · filed 2026-02-17 | $0.00 derived: sum of 3 quarters · filed 2026-02-17 | -$200.00K 10-K · filed 2026-02-17 |
| 2023-09-30 | $1.20M 10-Q · filed 2024-10-24 | -$1.60M derived: sum of 2 quarters · filed 2024-10-24 | -$1.80M 10-Q · filed 2024-10-24 | $2.20M derived: sum of 4 quarters · filed 2025-02-18 |
| 2023-06-30 | -$2.80M 10-Q · filed 2024-07-25 | -$3.00M 10-Q · filed 2024-07-25 | $1.00M derived: sum of 3 quarters · filed 2025-02-18 | $900.00K derived: sum of 4 quarters · filed 2025-02-18 |
| 2023-03-31 | -$200.00K 10-Q · filed 2024-04-25 | $3.80M derived: sum of 2 quarters · filed 2025-02-18 | $3.70M derived: sum of 3 quarters · filed 2025-02-18 | $2.80M derived: sum of 4 quarters · filed 2025-02-18 |
| 2022-12-31 | $4.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-18 | $3.90M derived: sum of 2 quarters · filed 2025-02-18 | $3.00M derived: sum of 3 quarters · filed 2025-02-18 | $1.40M 10-K · filed 2025-02-18 |
| 2022-09-30 | -$100.00K 10-Q · filed 2023-10-26 | -$1.00M derived: sum of 2 quarters · filed 2023-10-26 | -$2.60M 10-Q · filed 2023-10-26 | |
| 2022-06-30 | -$900.00K 10-Q · filed 2023-07-27 | -$2.50M 10-Q · filed 2023-07-27 | ||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-20 | $1.30M derived: sum of 2 quarters · filed 2024-02-20 | $2.50M derived: sum of 3 quarters · filed 2024-02-20 | $700.00K 10-K · filed 2024-02-20 |
| 2021-09-30 | $1.30M 10-Q · filed 2022-10-27 | $2.50M derived: sum of 2 quarters · filed 2022-10-27 | $700.00K 10-Q · filed 2022-10-27 | |
| 2021-06-30 | $1.20M 10-Q · filed 2022-07-28 | -$600.00K 10-Q · filed 2022-07-28 | ||
| 2020-09-30 | -$900.00K 10-Q · filed 2021-10-28 | -$3.60M derived: sum of 2 quarters · filed 2021-10-28 | -$1.00M 10-Q · filed 2021-10-28 | |
| 2020-06-30 | -$2.70M 10-Q · filed 2021-07-30 | -$100.00K 10-Q · filed 2021-07-30 | ||
| 2019-06-30 | $1.80M 10-Q · filed 2020-07-24 | -$1.50M 10-Q · filed 2020-07-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| DEXCOM INC (DXCM) | United States | $33.004B | 25.42 |
| Solventum Corp (SOLV) | United States | $15.085B | 9.16 |
| Penumbra Inc (PEN) | United States | $12.596B | 77.33 |
| BAXTER INTERNATIONAL INC (BAX) | United States | $12.139B | -10.35 |
| GLOBUS MEDICAL INC (GMED) | United States | $9.977B | 20.03 |
| INSULET CORP (PODD) | United States | $9.420B | 28.12 |
| GLAUKOS Corp (GKOS) | United States | $9.135B | -43.73 |
| MiniMed Group, Inc. (MMED) | United States | $5.748B | -16.85 |
| MERIT MEDICAL SYSTEMS INC (MMSI) | United States | $5.212B | 28.44 |
| TELEFLEX INC (TFX) | United States | $5.093B | -5.44 |